Trial Profile

A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Feb 2026 According to a Denali Therapeutics Inc media release, company announced that study design were presented presented this week at the 22nd Annual WORLDSymposium™ in San Diego, California.
06 Feb 2026 According to a Denali Therapeutics Inc media release, company announced that the U.S. FDA has lifted the clinical hold on the Investigational New Drug (IND) application for DNL952, and company will proceed with the Phase 1 study.
29 Jan 2026 According to a Denali Therapeutics Inc media release, data from the trial will be presented at the upcoming 22nd Annual WORLDSymposium to be held February 2-6, 2026, in San Diego, California.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com